NEUROCRINE BIOSCIENCES INC
For the period ended Dec 31, 2025. Filed Feb 11, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 11, 2026
NBIX$169.14+0.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
| Common Stock · AdditionalPaid-In Capital · AccumulatedOtherComprehensive Income (Loss) · Retained Earnings (Accumulated Deficit) · Total Stockholders’ Equity | |||||||
|---|---|---|---|---|---|---|---|
| (in millions) · Shares · $ | |||||||
| Balances at December 31, 2022 | 96.5 | $0.1 | $2,122.4 | $(7.9) | $(406.8) | $1,707.8 | |
| Net income | — | — | — | — | 249.7 | 249.7 | |
| Other comprehensive income, net of tax | — | — | — | 14.9 | — | 14.9 | |
| Stock-based compensation expense | — | — | 194.3 | — | — | 194.3 | |
| Issuances of common stock under benefit plans | 2.2 | — | 65.3 | — | — | 65.3 | |
| Balances at December 31, 2023 | 98.7 | $0.1 | $2,382.0 | $7.0 | $(157.1) | $2,232.0 | |
| Net income | — | — | — | — | 341.3 | 341.3 | |
| Other comprehensive loss, net of tax | — | — | — | (1.2) | — | (1.2) | |
| Stock-based compensation expense | — | — | 195.5 | — | — | 195.5 | |
| Issuances of common stock under benefit plans | 2.7 | — | 122.1 | — | — | 122.1 | |
| Repurchases of common stock | (2.0) | — | (145.0) | — | (155.0) | (300.0) | |
| Balances at December 31, 2024 | 99.4 | $0.1 | $2,554.6 | $5.8 | $29.2 | $2,589.7 | |
| Net income | — | — | — | — | 478.6 | 478.6 | |
| Other comprehensive income, net of tax | — | — | — | 7.3 | — | 7.3 | |
| Stock-based compensation expense | — | — | 217.9 | — | — | 217.9 | |
| Issuances of common stock under benefit plans | 2.5 | — | 127.3 | — | — | 127.3 | |
| Repurchases of common stock | (1.8) | — | (107.6) | — | (60.1) | (167.7) | |
| Balances at December 31, 2025 | 100.1 | $0.1 | $2,792.2 | $13.1 | $447.7 | $3,253.1 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.